论文部分内容阅读
目的:评价甘精胰岛素与瑞格列奈用于治疗2型糖尿病患者的临床疗效。方法:选取2014年2月—2015年2月间收治的2型糖尿病患者104例作为研究对象,并将其分为研究组与对照组,每组52例;所有患者均在控制饮食和坚持适当体育锻炼的基础上给予药物治疗,研究组患者均给予瑞格列奈片与甘精胰岛素治疗,对照组患者均给予精蛋白生物合成人胰岛素治疗,治疗12周后比较两组患者血糖控制情况及低血糖的发生率。结果:治疗后两组患者FPG、2 h PG及Hb A1c水平均显著低于治疗前(P<0.05);研究组患者FPG值与对照组比较其差异无统计学意义(P>0.05),而研究组2 h PG及Hb A1c水平显著低于对照组(P<0.05);治疗后研究组患者低血糖发生率为1.92%低于对照组为15.38%(χ2=7.081,P<0.05)。结论:甘精胰岛素与瑞格列奈联用治疗2型糖尿病患者的临床疗效优于单用精蛋白生物合成人胰岛素治疗,且低血糖的发生率较低,安全性较好。
Objective: To evaluate the clinical efficacy of insulin glargine and repaglinide in the treatment of type 2 diabetes. Methods: A total of 104 patients with type 2 diabetes who were admitted between February 2014 and February 2015 were selected as study subjects and divided into study group and control group, with 52 cases in each group. All patients were controlled diet and insisted on appropriate Physical therapy, medication was given on the basis of the physical therapy, the study group were given repaglinide tablets and insulin glargine, the control group were given protamine biosynthesis of human insulin treatment, after 12 weeks of treatment compared the two groups of patients with glycemic control The incidence of hypoglycemia. Results: The levels of FPG, 2 h PG and Hb A1c in the two groups after treatment were significantly lower than those before treatment (P <0.05). There was no significant difference in FPG between study group and control group (P> 0.05) The levels of PG and Hb A1c at 2 h in the study group were significantly lower than those in the control group (P <0.05). The incidence of hypoglycemia in the study group was 1.92% lower than that in the control group (χ2 = 7.081, P <0.05). Conclusion: The clinical efficacy of insulin glargine combined with repaglinide in patients with type 2 diabetes mellitus is better than that of human insulin alone treated with protamine biosynthesis, and the incidence of hypoglycemia is low and the safety is better.